The estimated Net Worth of Charles Anthony Laranjeira is at least $4.22 Milion dollars as of 14 June 2022. Mr. Laranjeira owns over 6,000 units of Pacira BioSciences Inc stock worth over $542,776 and over the last 6 years he sold PCRX stock worth over $3,676,878. In addition, he makes $0 as Chief Technical Officer at Pacira BioSciences Inc.
Charles has made over 8 trades of the Pacira BioSciences Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 6,000 units of PCRX stock worth $230,100 on 14 June 2022.
The largest trade he's ever made was selling 60,101 units of Pacira BioSciences Inc stock on 29 June 2020 worth over $3,021,277. On average, Charles trades about 7,933 units every 101 days since 2018. As of 14 June 2022 he still owns at least 41,752 units of Pacira BioSciences Inc stock.
You can see the complete history of Mr. Laranjeira stock trades at the bottom of the page.
Charles Laranjeira serves as Chief Technical Officer of the Company. He previously served as our Senior Vice President, Technical Operations from May 2017 until December 2018. Prior to joining Pacira, he was Vice President, Supply Operations of EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, from September 2015 until May 2016. Previously, he was Senior Vice President, Technical Operations of Cubist Pharmaceuticals, Inc., a biopharmaceutical company, from June 2011 until April 2015, and Vice President, Drug Product Manufacturing, Latin America, Asia Pacific & Japan at Bristol-Myers Squibb Company, a pharmaceutical company, from July 2009 until February 2011. Mr. Laranjeira holds a B.S. in Industrial Administration from the New Jersey Institute of Technology.
Charles Laranjeira is 54, he's been the Chief Technical Officer of Pacira BioSciences Inc since 2018. There are 17 older and 7 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Charles's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon a Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: